I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

GLP-1 agonists are used to treat diabetes and chronic weight management ... Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...

Since the 1990s, Novo Nordisk has operated a facility in Clayton, where it makes injectable finished products like insulin pens to treat diabetes. In the past few years however, the company has ...

In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by ...

The approval covers generic versions of two Novo Nordisk products: Victoza, used in the treatment of Type-2 Diabetes, and Saxenda, which is indicated for weight management. This marks a ...

Novo Nordisk’s revenue rose over 2x from 127 billion DKK in 2020 to 271 billion DKK for the last twelve-month period. This can primarily be attributed to the success of its diabetes and obesity ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...